Central Retinal Vein Occlusion (CRVO): Diagnosis and Treatment Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Central retinal vein occlusion (CRVO) is the second most common retinal vascular disorder after diabetic retinopathy, with an estimated prevalence of 0.1–0.3% in the adult population over 40 years of age. CRVO occurs when thrombosis develops in the central retinal vein at or posterior to the lamina cribrosa — the perforated plate of the sclera through which the central retinal artery and vein traverse. This single occlusion blocks venous drainage from the entire retina, causing diffuse, acute visual loss.

The pathophysiology of CRVO reflects Virchow's triad: endothelial damage at the arteriovenous crossing where the rigid central retinal artery compresses the vein within the shared connective tissue sheath; sluggish venous flow from systemic or ocular causes (hyperviscosity, raised intraocular pressure); and hypercoagulability from acquired or inherited thrombophilias. The occlusion results in elevated venous pressure transmitted throughout the retinal capillary network, causing haemorrhages in all four quadrants, disc oedema, dilated and tortuous retinal veins, and cystoid macular oedema (CMO) — the principal cause of vision loss.

CRVO is distinguished from branch retinal vein occlusion (BRVO), which occurs at arteriovenous crossings within the retina, affects only a sector of the retina, and generally has a better visual prognosis. CRVO disproportionately affects older adults (peak incidence 60–80 years) with systemic vascular risk factors, though younger patients (age 30–50 years) may present with CRVO related to hyperviscosity, thrombophilia, or systemic inflammatory disease.

Visual prognosis in CRVO varies considerably depending on the degree of retinal ischaemia. The landmark CRUISE trial (ranibizumab) and COPERNICUS/GALILEO trials (aflibercept) have established intravitreal anti-VEGF therapy as the standard of care for CRVO-associated macular oedema, replacing older approaches (grid laser photocoagulation, intravitreal triamcinolone) that proved less effective.

CRVO is classified into two main types based on the degree of retinal capillary non-perfusion, which determines prognosis and risk of neovascular complications.

Hayreh Ischaemic Classification: The original Hayreh classification divides CRVO into: Non-ischaemic CRVO (approximately 75% of cases) — less than 10 disc diameters (DD) of capillary non-perfusion on fluorescein angiography (FFA), preserved relative afferent pupillary defect (RAPD), visual acuity typically 6/60 or better, and better long-term prognosis. Ischaemic CRVO (approximately 25% of cases) — 10 or more DD of capillary non-perfusion on FFA (the "30DD or more" threshold used by some classifications denotes a severe ischaemic form), profound RAPD (a key clinical sign of ischaemia), initial visual acuity typically counting fingers or worse, and high risk of anterior segment neovascularisation (rubeosis iridis) and neovascular glaucoma (NVG).

• Macular Oedema (CMO): The most common cause of visual loss in CRVO. OCT demonstrates characteristic cystoid spaces in the inner and outer nuclear layers of the macula (central macular thickness typically >300 μm, often 500–700 μm at presentation). Subretinal fluid may also be present beneath the fovea. CMO responds to intravitreal anti-VEGF therapy and the dexamethasone implant (Ozurdex).
• Neovascular Glaucoma (NVG): A devastating complication of ischaemic CRVO, developing in approximately 20–40% of ischaemic cases within 90 days ("100-day glaucoma" — classical teaching). VEGF released from ischaemic retina drives anterior segment neovascularisation (iris and angle), causing refractory elevated IOP that can lead to irreversible blindness if untreated.
• Vitreous Haemorrhage: Rupture of fragile neovascular fronds from the disc or retina into the vitreous, causing sudden, dense visual loss (floaters progressing to complete obscuration). Requires vitrectomy if not clearing spontaneously.
• Retinal Detachment: Traction or combined tractional-rhegmatogenous retinal detachment from fibrovascular proliferative membrane contraction — a late complication in advanced neovascular disease.

All patients with suspected CRVO require a structured ophthalmic assessment to confirm diagnosis, classify ischaemic status, identify treatable complications (CMO, NVG), and guide treatment planning.

Ophthalmic Assessment: Best-corrected visual acuity (BCVA — Snellen or ETDRS logMAR) provides the primary outcome measure. Relative afferent pupillary defect (RAPD) assessment with a swinging torch is a critical bedside test: a significant RAPD (grade 2+) correlates with extensive retinal ischaemia and identifies patients at high NVG risk. Slit-lamp examination assesses anterior segment neovascularisation (rubeosis iridis — fine irregular new vessels on the iris surface, particularly at the pupillary margin and in the angle). Gonioscopy (angle neovascularisation assessment) and IOP measurement are mandatory. Fundoscopy and fundus photography document the characteristic features: diffuse flame-shaped and dot/blot haemorrhages in all four quadrants, disc oedema, dilated tortuous veins, and cotton wool spots (nerve fibre layer infarcts indicating retinal ischaemia).

Optical Coherence Tomography (OCT): OCT is the gold standard for assessing macular oedema in CRVO. Central macular thickness (CMT) is measured at baseline and at each follow-up visit. Treatment is indicated for CMT >300 μm (most centres use the threshold of >250 μm with associated VA loss). OCT also identifies subretinal fluid, intraretinal fluid distribution, ellipsoid zone (IS/OS layer) disruption (a negative prognostic indicator for final visual acuity), and epiretinal membrane formation.

Fluorescein Angiography (FFA): FFA quantifies the area of capillary non-perfusion (in disc diameters or mm² of retinal surface area) and classifies ischaemic vs non-ischaemic status. FFA findings in CRVO include: prolonged retinal arteriovenous transit time, venous staining and leakage, capillary non-perfusion (areas of hypofluorescence surrounded by dilated capillary tufts), late disc leakage, and macular CMO with petalloid leakage pattern. Ultra-widefield FFA provides superior assessment of peripheral retinal ischaemia.

Systemic Workup: All patients with CRVO, particularly those under 50 years, require a systemic evaluation: blood pressure measurement (hypertension present in 60–80% of CRVO cases); fasting lipid profile; fasting plasma glucose / HbA1c; full blood count (polycythaemia, thrombocythaemia); ESR and CRP (inflammatory vasculitis, sarcoidosis); thrombophilia screen (protein C, protein S, antithrombin III, factor V Leiden, antiphospholipid antibodies, homocysteine) — particularly in young patients and bilateral CRVO; serum protein electrophoresis (hyperviscosity syndromes); and IOP measurement (glaucoma is a major risk factor for CRVO due to raised pressure compressing the vein at the lamina cribrosa).

The therapeutic approach to CRVO depends on the presence and severity of macular oedema, degree of retinal ischaemia, IOP status, and presence of neovascular complications.

Intravitreal Anti-VEGF Therapy: Anti-VEGF agents are the first-line treatment for CRVO-associated macular oedema with visual acuity impairment. VEGF (vascular endothelial growth factor) is the principal mediator of CMO in CRVO and is markedly elevated in vitreous samples from affected eyes. Three agents have pivotal trial evidence:

• Ranibizumab (Lucentis, 0.5 mg/0.05 mL): CRUISE trial (Brown et al., Ophthalmology 2010) — 392 patients with CRVO and CMO, randomised to monthly ranibizumab 0.3 mg, 0.5 mg, or sham injection for 6 months, then PRN for months 7–12. Ranibizumab 0.5 mg resulted in mean BCVA gain of +14.9 ETDRS letters at 6 months (vs +0.8 letters for sham, p<0.001) and 47.7% gaining ≥15 letters vs 16.9% for sham. CMT reduction of 434 μm vs 168 μm. Gains largely maintained at 12 months with PRN dosing.
• Aflibercept (Eylea, 2 mg/0.05 mL): COPERNICUS trial (US, Boyer et al.) and GALILEO trial (rest of world, Holz et al.) — both demonstrated monthly aflibercept for 6 months followed by PRN dosing produced mean gains of +17.3 (COPERNICUS) and +18.0 (GALILEO) ETDRS letters at 24 weeks vs -4.0 and +3.3 letters for sham (p<0.001). At 52 weeks, COPERNICUS: +16.2 vs +3.8 letters. Aflibercept binds VEGF-A, VEGF-B, and placental growth factor (PlGF), offering theoretical advantages in multifactorial CMO.
• Bevacizumab (Avastin, 1.25 mg — off-label): Widely used off-label globally due to dramatically lower cost (approximately USD 50 vs USD 800–2,000 per injection for ranibizumab/aflibercept). Multiple comparative studies and meta-analyses show equivalent efficacy to approved agents for CRVO macular oedema, supporting bevacizumab as an appropriate first-line choice in resource-limited settings or where cost is a significant patient factor.

Dexamethasone Intravitreal Implant (Ozurdex, 0.7 mg): GENEVA trial (Haller et al., Ophthalmology 2010) — 1,267 patients with branch or central RVO. Ozurdex 0.7 mg achieved significantly greater proportion gaining ≥15 letters at 60 days (29.3% vs 9.1% sham, p<0.001). Effect peaks at 60 days and wanes by 6 months, requiring re-injection every 4–6 months. Key safety concerns: IOP elevation (>25 mmHg in 15–30% of injections, typically manageable with topical drops but occasionally requiring surgery); cataract progression (posterior subcapsular cataract in approximately 30% of phakic patients over 12 months). Ozurdex is particularly useful in pseudophakic patients, those anticoagulated (where anti-VEGF injection frequency is a concern), and patients who have failed anti-VEGF therapy.

Panretinal Photocoagulation (PRP) for Neovascular Complications: PRP is indicated when retinal or anterior segment neovascularisation develops (NVG, disc new vessels, retinal new vessels). PRP destroys ischaemic peripheral retina, reducing VEGF production and inducing neovascular regression. In NVG, intravitreal anti-VEGF injection rapidly regresses angle neovascularisation (allowing gonioscopy and trabeculectomy planning) and is combined with prompt PRP to address the ischaemic stimulus. Anti-VEGF alone (without PRP) in NVG leads to eventual neovascular recurrence as anti-VEGF effect wanes.

Surgical Options: Vitrectomy with epiretinal membrane peeling may reduce CMO refractory to medical therapy and relieve tractional retinal detachment. For persistent vitreous haemorrhage not clearing within 3 months, pars plana vitrectomy with membrane removal is indicated.

Anti-VEGF therapy and dexamethasone implant have transformed the natural history of CRVO-associated macular oedema, converting a condition with historically poor visual outcomes into one where significant, durable visual gains are achievable in a majority of patients.

Anti-VEGF Efficacy: The CRUISE trial established ranibizumab as highly effective, with 47.7% of treated patients gaining 15 or more ETDRS letters (approximately 3 Snellen lines) at 6 months — a clinically meaningful threshold — compared to only 16.9% of sham patients. The mean visual acuity gain of +14.9 letters in the ranibizumab 0.5 mg arm represents recovery from approximately 20/200 to 20/80 average vision. In the COPERNICUS trial, 60.2% of aflibercept-treated patients gained ≥15 letters at 24 weeks versus 18.8% of sham patients. These gains represent a dramatic improvement over the natural history of CRVO, in which spontaneous recovery of ≥15 letters occurred in only approximately 20% of non-ischaemic cases without treatment.

Long-Term Outcomes: Treat-and-extend (TAE) dosing regimens reduce the injection burden while maintaining visual gains achieved in the loading phase. Two-year data from CRUISE and GALILEO extensions demonstrate that monthly or near-monthly injections maintain mean visual acuity within 2–3 letters of the 6-month peak gain. Extended dosing intervals (>8–10 weeks) in PRN protocols may be associated with gradual CMT increase and partial VA loss, emphasising the importance of proactive monitoring.

GENEVA Trial Outcomes: Ozurdex achieved significantly faster initial visual gains (peak at 60 days) compared to anti-VEGF, making it advantageous when rapid recovery is clinically important. The proportion gaining ≥15 letters at 90 days (30.0% for 0.7 mg Ozurdex vs 12.3% for sham) compares favourably with the initial loading doses of anti-VEGF agents, though the duration of effect is shorter (4–6 months vs continuous monthly injection).

NVG Prevention: Prompt PRP combined with anti-VEGF therapy in ischaemic CRVO significantly reduces NVG risk. Early treatment series report NVG rates of 5–10% in ischaemic CRVO managed with anti-VEGF and PRP, compared to historical rates of 20–40% with observation alone. Achieving and maintaining IOP control prevents further optic nerve damage in eyes that have already sustained ischaemic retinal injury.

Treatment-related risks in CRVO management include complications of intravitreal injection procedures, drug-specific side effects, and laser-related adverse events.

Intravitreal Injection Risks: Each intravitreal injection carries a small but cumulative risk with repeated procedures. Endophthalmitis (bacterial infection of the vitreous) is the most serious, occurring in approximately 0.03–0.05% per injection at experienced centres. Signs include pain, redness, hypopyon, and visual loss within 1–7 days; requires emergency intravitreal antibiotic injection (vancomycin + ceftazidime). Rhegmatogenous retinal detachment occurs in approximately 0.01% per injection; iatrogenic lens touch (traumatic cataract) in <0.1%; subconjunctival haemorrhage is common (5–20%) and self-limiting. Systemic arterial thromboembolic events (stroke, MI) are a theoretical concern with anti-VEGF agents (pooled rate approximately 1.5–2.0% annually across injection trials), though causal attribution is difficult in a population with baseline vascular risk factors.

Dexamethasone Implant (Ozurdex) Risks: IOP elevation above 25 mmHg occurs in 15–30% of injections; the majority respond to topical anti-glaucoma medication (timolol, latanoprost, brimonidine, brinzolamide) and IOP normalises as the implant biodegrades over 4–6 months. However, patients with pre-existing glaucoma or severe optic nerve damage may suffer irreversible visual field loss from IOP spikes. Steroid-induced cataract (posterior subcapsular type) develops in approximately 30% of phakic patients within 12 months of first injection and progresses with subsequent implants, eventually requiring cataract surgery. Ozurdex is particularly well-tolerated in pseudophakic (post-cataract surgery) patients who do not carry cataract risk.

Panretinal Photocoagulation (PRP) Risks: PRP deliberately destroys peripheral retinal tissue to reduce VEGF production from ischaemic areas. Adverse effects include reduction in peripheral visual field (typically >20° peripheral field restriction after full PRP), reduced dark adaptation, worsening of night vision, and, rarely, inadvertent foveal burn causing central scotoma if landmarks are not correctly identified. PRP may also acutely worsen macular oedema (through laser-induced inflammation), requiring prophylactic anti-VEGF injection at the time of or shortly before PRP.

Natural History Risks (Untreated): Without treatment, ischaemic CRVO carries an approximately 20–40% risk of NVG development within 3 months and a very poor visual prognosis (most patients remain at counting fingers or hand motion VA). Non-ischaemic CRVO has a more favourable natural history (≥15 letter gain in approximately 20% spontaneously) but approximately 20% of non-ischaemic cases convert to ischaemic CRVO within 3 years, requiring vigilant monitoring.

CRVO requires intensive structured follow-up to monitor treatment response, detect reactivation of macular oedema, and screen for neovascular complications. Systemic risk factor management is a parallel and equally important component of long-term care.

Ophthalmic Follow-Up Schedule: During the initial loading phase (monthly anti-VEGF injections for 3–6 months): monthly BCVA assessment and OCT at every visit to guide injection decisions. After the loading phase, visits are scheduled monthly with injection decisions guided by OCT-defined CMT threshold (typically treat if CMT >300 μm or CMT increases by >50 μm from nadir, or if vision decreases by ≥5 ETDRS letters with corresponding CMT increase — treat-and-extend protocol). Minimum monitoring frequency in stable patients is every 6–8 weeks. FFA is repeated if neovascularisation is suspected or if OCT shows worsening CMO despite injections.

OCT Monitoring: OCT at each visit quantifies CMT (goal: CMT <300 μm), intraretinal fluid volume, and subretinal fluid status. Ellipsoid zone (IS/OS) integrity is assessed as a prognostic marker — disruption correlates with poor final BCVA regardless of CMT improvement. Resolution of subretinal fluid often lags behind intraretinal fluid resolution. Persistent ellipsoid zone disruption after CMO resolution predicts limited visual recovery and should be communicated to patients managing expectations.

Systemic Risk Factor Management: Blood pressure control is critical — a target of <130/80 mmHg (ESC 2018 hypertension guidelines) is recommended. Statin therapy for dyslipidaemia (LDL-C <2.0 mmol/L, or <1.8 mmol/L if the patient has concurrent CAD). Anti-platelet therapy (aspirin) is not routinely recommended for CRVO without concurrent systemic arterial disease indication (no evidence of benefit in RCTs). Thrombophilia identified on workup is managed by haematologist in collaboration with the ophthalmologist — anticoagulation with warfarin or LMWH may be indicated. IOP should be maintained below 21 mmHg; treatment of coexisting glaucoma (trabeculectomy, laser trabeculoplasty, topical drops) reduces risk of CRVO recurrence in the fellow eye.

Fellow Eye Monitoring: The fellow eye has an elevated risk of retinal vein occlusion — approximately 10% at 5 years for any RVO event. Annual fundoscopy and IOP measurement in the fellow eye are recommended. Gonioscopy assesses for occludable angles or early NVI in patients at vascular risk.

CRVO treatment is characterised by high ongoing injection costs due to the need for repeated intravitreal injections over months to years. Cost varies significantly by drug choice, country, and healthcare system.

Anti-VEGF Drug Costs: Ranibizumab (Lucentis): USD 1,800–2,000 per injection in the US; GBP 742 per injection under NHS England (NICE-approved); EUR 900–1,200 in Western Europe. Aflibercept (Eylea): USD 1,800–2,000 per injection in the US; GBP 816 under NHS tariff; EUR 900–1,200 in Western Europe. Bevacizumab (Avastin, off-label): USD 50–100 per repackaged injection globally — approximately 20-fold cheaper than branded anti-VEGF agents. Multiple systematic reviews and the CATT and IVAN trials (comparing bevacizumab vs ranibizumab in AMD) demonstrate equivalent visual outcomes, supporting bevacizumab as clinically appropriate where cost is a barrier.

Dexamethasone Implant (Ozurdex) Cost: USD 1,200–2,000 per implant in the US; GBP 870 per implant under NHS; EUR 800–1,400 in Europe. Fewer injections per year (approximately 2 implants vs 6–12 anti-VEGF injections for monthly dosing) partially offset the per-dose cost, and some pharmacoeconomic analyses demonstrate comparable total annual cost to anti-VEGF therapy.

Annual Treatment Cost Burden: Monthly anti-VEGF injections in year 1 (6–12 injections) cost USD 10,800–24,000 per year in the US at branded prices, or USD 600–1,200 per year with bevacizumab. The CRUISE extension demonstrated that injection frequency falls in year 2 (median approximately 3–4 PRN injections in year 2 vs 6 in year 1), reducing annual costs significantly.

Medical Tourism for Retinal Injections: International patients travel to India (LV Prasad Eye Institute, Aravind Eye Hospitals, Sankara Nethralaya), Thailand, and Turkey for intravitreal injections and retinal management. Ranibizumab injections in India cost approximately USD 200–400 per injection; aflibercept USD 300–500; bevacizumab USD 30–80. Annual injection packages at Indian retinal centres including OCT monitoring cost USD 1,500–5,000 for complete care — 70–90% savings compared to US pricing. Follow-up via telemedicine with OCT images shared electronically is offered by leading Indian retinal centres.

Several alternative or adjunctive treatments have been evaluated in CRVO, with most now considered inferior to intravitreal anti-VEGF therapy or relegated to specific niche indications.

Observation (Watchful Waiting) for Non-Ischaemic CRVO: In patients with non-ischaemic CRVO and mild macular oedema (CMT <300 μm) with preserved visual acuity (≥6/12, ≥70 ETDRS letters), observation with close monitoring every 4–6 weeks is a reasonable initial approach. Approximately 20% of non-ischaemic CRVO cases recover spontaneously without treatment. The decision to treat versus observe must balance injection burden and cost against the risk of progressive VA loss and CMO chronicity. The SCORE trial showed that intravitreal triamcinolone was not superior to observation in non-ischaemic CRVO with moderate macular oedema — supporting watchful waiting in mild cases.

Intravitreal Triamcinolone Acetonide (IVTA — off-label): A corticosteroid suspension used as a lower-cost alternative to Ozurdex in some countries. Provides temporary CMO reduction but with a shorter duration of effect (2–3 months) and a higher IOP elevation profile compared to Ozurdex. SCORE CRVO trial (Scott et al., Arch Ophthalmol 2009) showed intravitreal triamcinolone 1 mg and 4 mg were not superior to observation for non-ischaemic CRVO at 12 months. Role is now primarily limited to resource-limited settings where anti-VEGF or Ozurdex is not accessible.

Grid Laser Photocoagulation: The Central Vein Occlusion Study (CVOS, 1995) demonstrated that macular grid laser photocoagulation (targeting the perifoveal CMO area) reduced CMT in CRVO but did not improve visual acuity — the standard laser energy insufficient to override VEGF-driven CMO. Grid laser has been essentially abandoned as a first-line treatment for CRVO macular oedema since the advent of anti-VEGF therapy.

Systemic Anticoagulation: Despite CRVO's thrombotic aetiology, systemic anticoagulation (warfarin, LMWH) has not been shown to improve visual outcomes or prevent fellow-eye involvement in RCTs and is not recommended for CRVO management alone. It is indicated only when an underlying systemic hypercoagulable state (antiphospholipid syndrome, protein C/S deficiency, factor V Leiden) is identified on thrombophilia workup, managed in conjunction with a haematologist.

Haemodilution and Hyperviscosity Treatment: Isovolaemic haemodilution (reducing haematocrit to approximately 35% by venesection and plasma volume expansion) was investigated in small trials for hyperviscosity-related CRVO but showed no benefit in controlled studies. In patients with a confirmed hyperviscosity syndrome (polycythaemia vera, Waldenstrom macroglobulinaemia), treatment of the underlying haematological condition (venesection, cytoreductive therapy) takes priority and may improve visual outcomes.